TY - JOUR
T1 - Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines
T2 - Results of a multicenter phase II study
AU - Brandi, Mario
AU - Vici, Patrizia
AU - Lopez, Massimo
AU - Valerio, Maria Rosaria
AU - Giotta, F.
AU - Gebbia, Nicola
AU - Schittulli, Francesco
AU - Colucci, Giuseppe
PY - 2004/5
Y1 - 2004/5
N2 - The goals of this study were to evaluate the efficacy and toxicity of the gemcitabine/docetaxel combination in metastatic breast cancer previously treated with anthracyclines Fifty-three patients with metastatic breast cancer who had failed or relapsed after anthracycline-based chemotherapy entered the study and were evaluable. Patients received gemcitabine (1,000 mg/m2 days 1 and 8) and docetaxel (80 mg/m2 day 8), every 3 weeks. The regimen was generally well tolerated with good feasibility. A complete response occurred in six patients (9.4%) and partial response in 23 (43.4%) for an overall response rate of 53% (95% confidence interval, 38.9% to 66.7%). Median survival rate was 70%; and the duration of response, time to progression, and overall survival were 6, 7.5, and 16.5 months, respectively. We conclude that the gemcitabine/docetaxel combination constitutes a manageable and tolerable combination as salvage chemotherapy in metastatic breast cancer and may represent a valid treatment option in patients previously treated with anthracyclines.
AB - The goals of this study were to evaluate the efficacy and toxicity of the gemcitabine/docetaxel combination in metastatic breast cancer previously treated with anthracyclines Fifty-three patients with metastatic breast cancer who had failed or relapsed after anthracycline-based chemotherapy entered the study and were evaluable. Patients received gemcitabine (1,000 mg/m2 days 1 and 8) and docetaxel (80 mg/m2 day 8), every 3 weeks. The regimen was generally well tolerated with good feasibility. A complete response occurred in six patients (9.4%) and partial response in 23 (43.4%) for an overall response rate of 53% (95% confidence interval, 38.9% to 66.7%). Median survival rate was 70%; and the duration of response, time to progression, and overall survival were 6, 7.5, and 16.5 months, respectively. We conclude that the gemcitabine/docetaxel combination constitutes a manageable and tolerable combination as salvage chemotherapy in metastatic breast cancer and may represent a valid treatment option in patients previously treated with anthracyclines.
UR - http://www.scopus.com/inward/record.url?scp=2442643900&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2442643900&partnerID=8YFLogxK
M3 - Article
C2 - 15199527
AN - SCOPUS:2442643900
VL - 31
SP - 13
EP - 19
JO - Seminars in Oncology
JF - Seminars in Oncology
SN - 0093-7754
IS - 2 SUPPL. 5
ER -